A Phase 3 interventional study of Minodronic acid hydrate in Involutional Osteoporosis, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 9 sites in Japan. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-06-14.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.
1,675 studies on the registry are indexed under Osteoporosis; 211 are open to participants now.
This study's enrollment of 444 is above the median of 95 across 1,152 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
New fragility vertebral fracture
New clinical fracture, biochemical markers of bone turnover, height, mean bone mineral density of the lumbar spine (L2-4 BMD), lower back pain.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: YM 529
Ono Pharmaceutical Co., Ltd. →